購読する
モデル製品
サービス
前臨床薬効評価
コミュ二ティー
huHSC-NKG-ProN Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huHSC-NKG-ProN Mouse
製品名
huHSC-NKG-ProN Mouse
製品ID
C001545
系統名
huHSC-ProN-NOD.Cg-PrkdcscidIl2rgem1cya/Cya
背景情報
NKG
状況
このマウス系統を論文で使用する場合は、「huHSC-NKG-ProN Mouse（カタログ番号C001545）はサイアジェンから購入しました。」と引用してください。
Immunodeficient Mice
Humanized Immune System Models
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
Immunodeficient Mice
Humanized Immune System Models
基本情報
検証 Data
関連リソース
基本情報
遺伝子名
遺伝子別名
gc, p64, [g]c, CD132, gamma(c)
NCBI ID
染色体
Chr X
MGI ID
さらに
系統詳細
NKG mice (Catalog number: C001316) are severely immunodeficient mice generated by Cyagen through deleting the Il2rg gene from NOD-Scid mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for the transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenografts (PDX).
huHSC-NKG mice are immune system humanized mouse models constructed by transplanting human hematopoietic stem cells (HSC) into NKG mice after sub-lethal dose irradiation. This model has a long lifespan and can successfully reconstitute various immune cells. In addition, huHSC-NKG mice typically do not develop graft-versus-host disease (GvHD) and the reconstitution period can be long.
The huHSC-NKG-ProN mouse is the latest enhanced version of the huHSC-NKG series, where "Pro" indicates the enhanced series and "N" specifically refers to NK cells (Natural Killer cells). This mouse utilizes advanced neonate technology and has been process-optimized to allow for the development of lymphoid T cells and B cells, as well as NK cells, with minimal myeloid development. It is suitable for research on immune checkpoint inhibitors, ADCC (Antibody-Dependent Cell-mediated Cytotoxicity) mechanisms, and in vivo CAR-NK cell therapy.
適用分野
Tumor Immunology Research: Suitable for research on immune checkpoint inhibitors, ADCC (Antibody-Dependent Cell-mediated Cytotoxicity) mechanisms, and in vivo CAR-NK cell therapy;
Drug Metabolism and Toxicity Research: Assessment of the pharmacokinetic properties and toxic effects of candidate compounds in vivo.
検証 Data
1. Survival and Growth Curves
During the process of human immune system reconstitution, the body weight of NKG mice reached 19-21 grams by 12 weeks post-reconstitution, and the survival rate at 18 weeks post-reconstitution was 90%.
Figure 1. Survival and body weight changes in NKG mice following human hematopoietic stem cells (HSCs) transplantation.
2. Reconstitution of Human Leukocytes in Peripheral Blood
Transplantation of human umbilical cord blood-derived hematopoietic stem cells (HSCs) into NKG mice for human immune system reconstitution resulted in a stable reconstitution efficacy, with the proportion of human-derived CD45+ leukocytes reaching approximately 40%-60%.
Figure 2. Reconstitution of human CD45+ leukocytes in the peripheral blood of NKG mice following transplantation of human HSCs.
3. Reconstitution of Human T Cells and B Cells in Peripheral Blood
Effective T cell reconstitution commenced from the 10th week post-transplantation of human hematopoietic stem cells (HSCs), with the mean T cell content reaching 40% by the 14th week. The proportion of B cells exceeded 80% during weeks 6-8 post-reconstitution. Subsequently, as the proportions of T cells and NK cells increased, the B cell proportion decreased to 20%-40%.
Figure 3. Reconstitution of human T cells and B cells in the peripheral blood of NKG mice following transplantation of human HSCs.
4. Reconstitution of Human NK Cells and Monocytes in Peripheral Blood
The average reconstitution proportion of Natural Killer (NK) cells is approximately 5%-20%, and the reconstitution proportion of monocytes is below 1%.
Figure 4. Reconstitution of human NK cells and monocytes in the peripheral blood of NKG mice following transplantation of human HSCs.
関連リソース
お問い合わせ
ご不明な点やご質問などございましたら、お気軽にお問い合わせください。担当スタッフがサポートさせていただきます。下記のフォームにご記入いただければ、1〜2営業日以内に折り返しご連絡いたします。
Related Product
All Related ProductsResources
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。